2023-12-13 07:28:21 ET
DENVER, Colo., Dec 13, 2023 ( www.247marketnews.com )- Shattuck Labs, Inc. (NASDAQ: STTK) reported, this morning, initial topline dose-expansion data from its ongoing Phase 1A/B clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients. Initial data from the dose-expansion cohorts build on the complete dose-escalation data featured in a poster presentation on December 11, 2023 at the 65th ASH Annual Meeting.
Observations include a 79% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete response (CR)/marrow complete response (mCR) rate of 64%; 27% initial CR/complete response with incomplete hematologic recovery (CRi) in frontline TP53m AML patients, and 5/11 evaluable patients achieved stable disease with decreasing blast counts and peripheral …
The post Positive Initial Topline Data from Ongoing Phase 1 Clinical Trial could make This Today’s Trade appeared first on 24/7 Market News .
For further details see:
Disclaimer
This article is for the purposes of solicitation subscriptions for this website. This website expects to generate new advertisement revenue resulting from the distribution of this article. The amount of which is unknown at this time. This website or it’s authors do not own any shares of Shattuck Labs Inc. (STTK) and does not buy, sell, or trade any shares of (STTK). This article does not provide a professional analysis of a (STTK) financial position. (STTK) financial position and all other information regarding the featured Company should be verified directly with (STTK). Please read our full disclaimer for more detailed information.
